Editor's Picks
What next for healthcare CVC in 2023?
What's going to happen to healthcare startup funding this year? Will the IPO market recover? And what kinds of technologies are on the up? We asked some leading CVCs for their view.
Has Corporate Venture Capital unleashed its full potential yet?
Guest comment by Stefan Gabriel, Hitachi Ventures
CVC in the Time of Coronavirus: Shinichiro Hori, YJ Capital
Despite uncertainty, Yahoo Japan’s corporate venturing vehicle will continue its efforts in innovation and technology in the Japanese ecosystem through collaborations with startups.
CVC in the Time of Coronavirus: Blake Luse, Ferguson Ventures
Ferguson's investment arm is in weekly contact with portfolio companies and expects digitisation to be more widely adopted in the construction industry as work practices change.
CVC in the Time of Coronavirus: Nicolas Sauvage, TDK Ventures
TDK's corporate venturing unit is lining up more deals to go with its investment in Genetesis this week, having been formed early last year with one eye on an economic downturn.
CVC in the Time of Coronavirus: Jason Miles, VFS Innovation Ventures
Although newly formed, Volvo Financial Services' strategic investment arm is optimstic about the potential of mature technologies meeting more inviting valuations.
CVC in the Time of Coronavirus: Girish Nadkarni, Total Carbon Neutrality Ventures
Total Carbon Neutrality Ventures' international outlook has eased the switch to remote working somewhat, and opportunities are available for careful investors.
CVC in the Time of Coronavirus: Lisa Lambert, National Grid Partners
Lambert told GCV she believes investors will continue to back portfolio companies, but the inability to meet potential portfolio companies on the ground will hinder new investments.